Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in MASLD/NAFLD Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease
NCT07585526Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of finerenone in chronic kidney disease (CKD) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Incidence of chronic kidney disease at 6 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07585526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07585526.